Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation-Reference-Cited by-同舟云学术

Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation

Published:2022-03-11 Issue:1 Volume:25 Page:367-380
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Cheng Wendy Y.¹^ORCID,Avery Robin K.²^ORCID,Thompson-Leduc Philippe¹^ORCID,Cheung Hoi Ching¹,Bo Tien³,Duh Mei Sheng¹^ORCID,Hirji Ishan⁴

Affiliation:

1. Health Economics and Outcomes Research, Analysis Group, Inc, Boston, MA, USA

2. Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD, USA

3. Medical Affairs, Takeda Development Center Americas, Inc, Lexington, MA, USA

4. Global Evidence & Outcomes, Takeda Development Center Americas, Inc, Lexington, MA, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2022.2046388

Reference42 articles.

1. CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION

2. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis

3. Cytomegalovirus Serology and Replication Remain Associated With Solid Organ Graft Rejection and Graft Loss in the Era of Prophylactic Treatment

4. Cytomegalovirus Infections after Hematopoietic Stem Cell Transplantation: Current Status and Future Immunotherapy

5. Correlation of Cytomegalovirus (CMV) Disease Severity and Mortality With CMV Viral Burden in CMV-Seropositive Donor and CMV-Seronegative Solid Organ Transplant Recipients

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost‐effectiveness of maribavir versus conventional antiviral therapies for post‐transplant refractory cytomegalovirus infection with or without genotypic resistance: A US perspective;Journal of Medical Virology;2024-04

2. Approaches and Challenges in the Current Management of Cytomegalovirus in Transplant Recipients: Highlighting the Role of Advanced Practice Providers (Nurse Practitioners and Physician Assistants);Annals of Transplantation;2024-03-15

3. A time trade-off study to determine health-state utilities of transplant recipients with refractory cytomegalovirus infection with or without resistance;Health and Quality of Life Outcomes;2024-03-06

4. Treatment for First Cytomegalovirus Infection Post–Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir;Clinical Infectious Diseases;2023-11-30

5. What’s New: Updates on Cytomegalovirus in Solid Organ Transplantation;Transplantation;2023-10-30